Cosmo Pharmaceuticals NV
SIX:COPN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
43.8
104.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Wall Street
Price Targets
COPN Price Targets Summary
Cosmo Pharmaceuticals NV
According to Wall Street analysts, the average 1-year price target for
COPN
is 105.83 CHF
with a low forecast of 82.82 CHF and a high forecast of 136.5 CHF.
Operating Income
Forecast
Operating Income Estimate
Cosmo Pharmaceuticals NV
For the last 13 years the
compound annual growth rate for
Cosmo Pharmaceuticals NV's operating income is
24%.
The projected
CAGR
for the next 3 years is
-37%.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is COPN's stock price target?
Price Target
105.83
CHF
According to Wall Street analysts, the average 1-year price target for
COPN
is 105.83 CHF
with a low forecast of 82.82 CHF and a high forecast of 136.5 CHF.
What is Cosmo Pharmaceuticals NV's Revenue forecast?
Projected CAGR
-17%
For the last 13 years the
compound annual growth rate for
Cosmo Pharmaceuticals NV's revenue is
17%.
The projected
CAGR
for the next 3 years is
-17%.
What is Cosmo Pharmaceuticals NV's Operating Income forecast?
Projected CAGR
-37%
For the last 13 years the
compound annual growth rate for
Cosmo Pharmaceuticals NV's operating income is
24%.
The projected
CAGR
for the next 3 years is
-37%.
What is Cosmo Pharmaceuticals NV's Net Income forecast?
Projected CAGR
-35%
For the last 13 years the
compound annual growth rate for
Cosmo Pharmaceuticals NV's net income is
25%.
The projected
CAGR
for the next 3 years is
-35%.
